$7.260
-0.863 (-11.89%)終値時点
EIKN の同業比較
In the context of the broader market, EIKN competes directly with industry leaders such as SPRY and ASMB. With a market capitalization of $393.24M, it holds a significant position in the sector. When comparing efficiency, EIKN's gross margin of N/A stands against SPRY's 61.83% and ASMB's 100.00%. Such benchmarking helps identify whether Eikon Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.
Eikon Therapeutics Inc の財務パフォーマンス
Eikon Therapeutics has reported consistent net losses, with Q2 2026 showing a net income of -88,409,000. The EPS for Q2 2026 was -1.63, which is worse than the expected -1.61, indicating financial instability. The current ratio has been fluctuating, but it was 9.89 in Q2 2026, suggesting some liquidity.
Financials
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。